Placeholder

Calcipotriol

  • # LGM Pharma is a Calcipotriol CAS# 112965-21-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Calcipotriol
  • CAS #: 112965-21-6
  • Mode of Action:

    The precise mechanism of calcipotriol in remitting psoriasis is not well-understood. However, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor, while being less than 1% as active as the calcitriol in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis, and it is thought that the binding of calcipotriol to the VDR modulates the T cells gene transcription of cell differentiation and proliferation related genes.

  • Pharmacodynamics:

    Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin.

  • Metabolism:

    Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound.

  • Toxicity:

    Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.

  • IUPAC: (1R, 3S, 5Z)-5-{2-[(1R, 3aS, 4E, 7aR)-1-[(2R, 3E, 5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1, 3-diol
  • ATC: D05AX02
  • PubChem: 5288783
  • DrugBank: DB02300 (EXPT02131)
  • Formula: C18H19N3O5S
  • Molecular Mass: 412.6047
  • Synonyms: Calcipotriene
  • SMILES: O[C@H](C=C[C@@H](C)[C@@]1([H])CC[C@@]2([H])C(CCC[C@]12C)=CC=C1C[C@@H](O)C[C@H](O)C1=C)C1CC1
  • InChl: LWQQLNNNIPYSNX-UROSTWAQSA-N
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service